Lobbying client · LD-2 disclosures
Novartis Corp
District of Columbia
9 filings from 1 registrant · 2008–2010 · latest filed Oct 18, 2010
Reported on its behalf
$530K
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$530K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Budget/Appropriations
BUD
9 filings
$530K on those filings
Health Issues
HCR
9 filings
$530K on those filings
Copyright/Patent/Trademark
CPT
Bills named in the filings
The 15 most-cited of 27 bill references, extracted from the activity descriptions.
Who did the lobbying
Every lobbyist named on this client's filings.
- Steve Symms Parry, Romani, Deconcini & Symms9 filingsthrough 2010
- Romano Romani Parry, Romani, Deconcini & Symms9 filingsthrough 2010
- Edward H Baxter Parry, Romani, Deconcini & Symms9 filingsthrough 2010
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: novartis-corp.